Ribomic Inc. (TYO:4591)

Japan · Delayed Price · Currency is JPY

73.00

0.00 (0.00%)

Jul 16, 2026, 10:58 AM JST

-37.07% (1Y)

Market Cap	4.08B -16.0%
Revenue (ttm)	3.00M +50.0%
Net Income	-1.15B
EPS	-23.06
Shares Out	55.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	736,200
Open	73.00
Previous Close	73.00
Day's Range	72.00 - 74.00
52-Week Range	57.00 - 127.00
Beta	0.18
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Ribomic

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. The company was incorporated in 2003 and is headquartered in Tokyo, Japan. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2003

Employees 25

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4591

Full Company Profile

Financial Performance

In fiscal year 2026, Ribomic's revenue was 3.00 million, an increase of 50.00% compared to the previous year's 2.00 million. Losses were -1.15 billion, 12.5% more than in 2025.

Financial Statements